On May 19-21, 2026, the 2026 Future Healthcare Annual Lists & Awards was grandly launched in Shanghai. With its profound independent innovation capability and strong market product competitiveness, Zhuhai Trinomab Biopharmaceutical Co., Ltd. (hereafter referred to as "Trinomab") won two prestigious industry awards - " China Future Healthcare Rankings 2026-Top 100 Innovative Biopharmaceutical Companies " and " Top 50 Innovative Influencers in China's Healthcare Industry ". This marks the fourth consecutive year that Trinomab has been listed on this authoritative ranking, fully demonstrating the company's comprehensive strength and industry value in the field of innovative biopharmaceuticals. The China Future Healthcare Rankings are highly credible and influential professional evaluations within China's healthcare sector, attracting widespread attention from major investment institutions, industrial capital, and industry peers. They have become a significant indicator for understanding the development trends of the medical and health industry, guiding industry innovation, and directing capital investment layout.
Product Innovation Driven:
Positioned Among the Top 100 Through Systematic Innovation
The " China Future Healthcare Rankings 2026-Top 100 Innovative Biopharmaceutical Companies" focuses on enterprises engaged in R&D, production, or providing innovative therapies for innovative drugs and biological products, covering cutting-edge areas such as antibodies, vaccines, cell therapy, and gene therapy. It aims to select pharmaceutical companies with strong annual product competitiveness, outstanding innovation attributes, excellent clinical and commercial values, and high growth potential.
Trinomab's inclusion in this ranking is closely related to its systematic innovation in technology platforms, product pipelines, and commercialization progress. Relying on its independently owned high-throughput human antibody technology platform HitmAb, the company focuses on infectious diseases and pain disorders. It has built a tiered pipeline matrix ranging from marketed products to late-stage clinical trials and early-stage research and development. Its core product, Siltartoxatug Injection is the world's first anti-tetanus toxin monoclonal antibody. Produced through recombinant DNA technology, it breaks free from the dependence on traditional human or equine serum products. A single injection can achieve rapid effect and provide protection for over 90 days, fundamentally revolutionizing the traditional tetanus prevention method that has been used for a century. In the same year, this drug was honored by the international top journal 《Nature Medicine》 based on solid Phase III clinical data, showcasing its leading global innovation capabilities. In December 2025, Siltartoxatug Injection was successfully included in the national medical insurance catalogue and has been implemented nationwide starting since January 1, 2026. Being included in the medical insurance within one year after market launch reflects the support for true innovation: opening channels for breakthrough therapies with differentiated clinical values, accelerating innovative treatments to patients, and significantly improving patient accessibility.
In February 2026, the company's independently developed anti-respiratory syncytial virus (RSV) full-human monoclonal antibody - Retavibart Injection monoclonal antibody injection - had its new drug application (NDA) officially accepted by the National Medical Products Administration (NMPA), and was included in the NMPA's priority review and approval process, accelerating its market entry process. Trinomab continues to invest in independent innovation through its self-owned technology platform, bringing safer and more accessible treatment options to patients.
Technology + Industry Synergy:
Interpreting Innovative Influence with Dual Roles
The 2026 "Top 50 Innovative Influencers in China's Healthcare Industry " award has been upgraded and no longer honors individuals based on a single role. Instead, it breaks down barriers between entrepreneurs, scientists, and investors, focusing on individuals' linkage practices in key areas such as technological breakthroughs, achievement transformation, and capital empowerment, as well as their ecological influence on industrial collaborative innovation and upgrading.
Liao Huaxin, co-founder, chairman, and chief of technology officer of Trinomab, was selected as a vivid example of this selection concept. As a globally renowned immunologist and virologist with over 40 years of research experience, Dr. Liao served as a professor and Research Director of the Human Vaccine Institute at Duke University, where he played outstanding scientific research and leadership role in the fight against AIDS as well as the other infectious diseases. At the end of 2015, he co-founded Trinomab with Zheng Weihong who has extensive experience in the pharmaceutical industry, thus starting the "bench to bedside" full industrial chain process. Over ten years, Trinomab has grown from a two-person team to its current workforce of nearly 900 employees today and evolved into a full-service pharmaceutical enterprise. As a representative of scientific entrepreneurship, Dr. Liao has established an efficient pathway between technological origins and industrial implementation. His personal influence spans multiple value nodes from basic research, drug development to industrialization, effectively driving the systematic translation of pioneering innovations into tangible real clinical value. This deeply aligns with the award's selection theme of recognizing "core figures who break role barriers and play key roles in the entire chain of industrial innovation."
Securing the China Future Healthcare rankings for four consecutive years is not only a high recognition of Trinomab's past innovative achievements but also a full affirmation of its future development prospects. Currently, the company is at a critical stage from commercialization startup to higher scale expansion – Siltartoxatug Injection has been included in the national medical insurance, NDA for anti-RSV monoclonal antibody drug- Retavibart Injection has been accepted with priority review, and its IPO application on the Science and Technology Innovation Board has successfully passed the meeting review. The company continues to advance its innovative pipeline. Trinomab is committed to developing, manufacturing, and commercializing full-human monoclonal antibody new drugs to meet unmet clinical needs and benefit global patients with its mission of "creating clinical value." In the future, the company will continue to delve into the monoclonal antibody field, speed up the R&D and industrialization processes of key drug candidates in the pipeline, and unlock greater clinical and social value, and contribute more "Chinese innovation" to health care in China and worldwide.
(The above images are sourced from official live streaming pictures of artery network activities)
